NCT03907475View on ClinicalTrials.gov

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

July 16, 2019

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
Interventions
PROCEDURE

Biopsy Procedure

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Capecitabine

Given PO

DRUG

Carboplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Durvalumab

Given IV

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Nab-paclitaxel

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

Trial Locations (1)

20892

RECRUITING

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH